Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 5 studies | 19% ± 4% | |
immature B cell | 3 studies | 21% ± 5% | |
hepatocyte | 3 studies | 36% ± 13% | |
alveolar macrophage | 3 studies | 25% ± 3% | |
naive B cell | 3 studies | 21% ± 3% | |
plasmacytoid dendritic cell | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of KMO at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 2164.69 | 226 / 226 | 76% | 6.09 | 310 / 406 |
kidney | 100% | 731.39 | 89 / 89 | 72% | 8.24 | 653 / 901 |
breast | 83% | 42.44 | 380 / 459 | 70% | 4.18 | 781 / 1118 |
lung | 100% | 264.21 | 576 / 578 | 52% | 1.24 | 604 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 100% | 7.20 | 29 / 29 |
spleen | 100% | 665.52 | 241 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 94% | 56.22 | 243 / 258 | 3% | 0.04 | 6 / 230 |
peripheral blood | 95% | 202.97 | 886 / 929 | 0% | 0 | 0 / 0 |
thymus | 82% | 33.95 | 535 / 653 | 9% | 0.15 | 52 / 605 |
intestine | 78% | 62.97 | 757 / 966 | 12% | 0.22 | 62 / 527 |
skin | 38% | 11.63 | 686 / 1809 | 48% | 1.64 | 227 / 472 |
adipose | 85% | 67.59 | 1029 / 1204 | 0% | 0 | 0 / 0 |
stomach | 61% | 20.81 | 218 / 359 | 16% | 0.30 | 46 / 286 |
brain | 59% | 35.42 | 1571 / 2642 | 14% | 0.31 | 101 / 705 |
bladder | 52% | 15.62 | 11 / 21 | 18% | 0.51 | 93 / 504 |
prostate | 63% | 28.84 | 154 / 245 | 1% | 0.02 | 6 / 502 |
esophagus | 44% | 12.13 | 631 / 1445 | 17% | 0.32 | 32 / 183 |
pancreas | 24% | 6.72 | 80 / 328 | 28% | 0.52 | 50 / 178 |
uterus | 34% | 14.63 | 57 / 170 | 11% | 0.29 | 49 / 459 |
blood vessel | 44% | 22.63 | 582 / 1335 | 0% | 0 | 0 / 0 |
ovary | 31% | 8.36 | 55 / 180 | 12% | 0.19 | 50 / 430 |
heart | 27% | 9.68 | 235 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 22% | 0.38 | 10 / 45 |
muscle | 2% | 0.50 | 19 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019805 | Biological process | quinolinate biosynthetic process |
GO_0097052 | Biological process | L-kynurenine metabolic process |
GO_0009651 | Biological process | response to salt stress |
GO_1903296 | Biological process | positive regulation of glutamate secretion, neurotransmission |
GO_0070189 | Biological process | kynurenine metabolic process |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0006569 | Biological process | tryptophan catabolic process |
GO_0034354 | Biological process | 'de novo' NAD biosynthetic process from tryptophan |
GO_0019674 | Biological process | NAD metabolic process |
GO_0043420 | Biological process | anthranilate metabolic process |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0034276 | Biological process | kynurenic acid biosynthetic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005829 | Cellular component | cytosol |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0050660 | Molecular function | flavin adenine dinucleotide binding |
GO_0071949 | Molecular function | FAD binding |
GO_0004502 | Molecular function | kynurenine 3-monooxygenase activity |
GO_0016174 | Molecular function | NAD(P)H oxidase H2O2-forming activity |
Gene name | KMO |
Protein name | Kynurenine 3-monooxygenase Kynurenine 3-monooxygenase (EC 1.14.13.9) (Kynurenine 3-hydroxylase) |
Synonyms | |
Description | FUNCTION: Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn) . Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract (Probable). . FUNCTION: Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. . FUNCTION: Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. . |
Accessions | A8K693 O15229 ENST00000366558.7 [O15229-2] ENST00000366555.5 Q9BS61 H0Y320 ENST00000366559.9 [O15229-1] ENST00000366557.8 [O15229-3] |